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To evaluate differences in analytical performance and clinical results of BNP and NT-proBNP immunoassays, a
proﬁciency testing program, called CardioOrmoCheck study, has been organized since 2005 under the patronage
of the Study Group of the Cardiovascular Biomarkers of the Italian Society of Clinical Biochemistry (SIBIOC). On
average more than 100 Italian laboratories were involved in the annual 2005–2011 cycles.
In total, 72 study samples were distributed andmeasured by participant laboratories for a total of 6706 results. A
great difference in between-method variability was found between BNP (43.0 CV%) and NT-proBNP (8.7 CV%)
immunoassays. However, with the only exception of the POCTmethod for BNP assay, all immunoassay methods
showed an imprecision≤10 CV% at the cut-off levels (i.e. 100 ng/L for BNP and 400 ng/L for NT-proBNP assay,
respectively). Furthermore, CardioOrmoCheck study demonstrated that the most popular BNP immunoassays
are affected by large systematic differences (on average more than 2 folds between TRIAGE Beckman-Coulter
and ADVIA Centaur Siemens methods), while the agreement between NT-proBNP methods was better.
CardioOrmoCheck study demonstrates that there are marked differences in analytical performance and measured
values in particular among commercialmethods for BNP assay. Theseﬁndings suggest that itmay be not reasonable
to recommend identical cut-off or decision values for all BNP immunoassays.
© 2012 Elsevier B.V. All rights reserved.
1. Introduction
Cardiac natriuretic peptides, which include the atrial natriuretic pep-
tide (ANP) and B-type natriuretic peptide (BNP) and their related pep-
tides, constitute a complex family of peptide hormones produced and
secreted by the heart [1–3]. The active peptides, ANP and BNP, are pro-
duced by cleavage of COOH-terminal part of the pro-hormone (proANP
and pro-BNP), while the N-terminal fragments of pro-hormone,
NT-proANP and NT-proBNP, are currently considered inactive [1–3].
The measurement of circulating BNP and its related-peptides is
now considered to be a useful marker of myocardial function [1–6],
and recent international guidelines recommend its use for the diagnosis,
risk stratiﬁcation, and follow-up of patients with chronic or acute heart
failure [5–7]. Some meta-analyses [8,9] conﬁrmed that both BNP and
NT-proBNP immunoassays have a high degree of diagnostic accuracy
and clinical relevance in both acute and chronic heart failure. However,
very recent studies suggested that a great part of B-type natriuretic pep-
tides measured in patients with cardiovascular disease is devoid of any
biological activity [2,3,10–12].
In order to evaluate the differences in analytical performance and
clinical results of themost popular BNP and NT-proBNP immunoassays,
a proﬁciency testing study, based on an external quality assessment
scheme and called CardioOrmoCheck, have been organized and carried
out in Italy since January 2005. Previous, preliminary results of the
CardioOrmoCheck study suggested that there are signiﬁcant differ-
ences in analytical characteristics and measured values among the
most popular commercial methods for B-type related natriuretic
peptides, especially among the immunoassays considered speciﬁc for
BNP. In particular, a 2.7 fold difference was on average found between
the BNP values measured by the two methods reporting the highest
and the lowest values, respectively [13]; while the NT-proBNP immuno-
assays showed only slight differences in both imprecision andmeasured
values. These differences are probably due to the different crossreactions
against the precursor proBNP and other related peptides shared by BNP
immunoassays [14]; although some differences in the standard material
used for the curve calibration cannot be excluded. According to these
data [13,14], the most part of peptides measured by so-called BNP
Clinica Chimica Acta 414 (2012) 112–119
⁎ Corresponding author at: Laboratory of Cardiovascular Endocrinology and Cell Biology,
Fondazione Toascana G. Monasterio, Via Trieste 41, 56126 Pisa, Italy. Tel.: +39 0585
493569; fax: +39 0585 493601.
E-mail address: clerico@ifc.cnr.it (A. Clerico).
0009-8981/$ – see front matter © 2012 Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.cca.2012.07.017
Contents lists available at SciVerse ScienceDirect
Clinica Chimica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /c l inch im
Author's personal copy
immunoassays in patients with heart failure may be inactive. Moreover,
signiﬁcant differences in imprecision among methods were previously
observed in the CardioOrmoCheck study [13]. These different analytical
performances, concerning both measured values and analytical impreci-
sion, may strongly affect the clinical usefulness of BNP immunoassay
methods. However, in spite of these great differences in analytical and
clinical performances, the most recent international guidelines [5,7]
still suggest identical decisional values for all BNP (i.e., 100 ng/L) and
NT-proBNP (i.e. 400 ng/L) immunoassay methods.
In the present article, authors reported the results obtained by the
CardioOrmoCheck study throughout all the 7 years of the activity of the
collaboratirve program (i.e., from 2005 to 2011 cycle). In particular, the
greatly increased number of results available (i.e., 6706 results, 3269 for
BNP and 3446 for NT-proBNP assay), compared to a previous report
(i.e., 2354 results) [13], allowed a better evaluation of imprecision
proﬁles of the most popular immunoassay methods of the survey and
so an accurate estimation of CV conﬁdence intervals, concerning
the decisional values. Furthermore, the increasing number of study
samples with different matrix (i.e., serum, EDTA or heparin plasma),
tested in the study, allowed a more accurate evaluation of the possible
matrix effect on the performance of BNP and NT-proBNP immunoassays.
2. Materials and methods
2.1. Collaborative study
The CardioOrmoCheck study is a proﬁciency testing program for
the measurement of BNP and NT-proBNP, organized in Italy since
2005 under the patronage of the Study Group of the Cardiovascular
Risk Biomarkers of the Italian Society of Clinical Biochemistry
(SIBIOC) by three accredited (ISO 9001 accreditation) laboratories:
QualiMedLab srl, working at CNR Institute of Clinical Physiology and
Fondazione Regione Toscana G. Monasterio of Pisa, Department of
Laboratory Medicine, University-Hospital of Padova, and Biomedical
Research Centre of Castelfranco Veneto, Italy. On average, more than
100 Italian laboratories were involved in the annual 2005–2011 cycles.
In particular, in the last cycle (year 2011), 130 Italian laboratories par-
ticipated in the CardioOrmoCheck study: 55 laboratories used BNP,
while 75NT-proBNPmethods. Themajor part (about 85%) of the partic-
ipant laboratories was hospital labs, while the remaining part included
private laboratories.
2.2. Sample preparation
In total, 72 study samples with different BNP/NT-proBNP concentra-
tions were prepared by the central laboratories of the study (Supple-
mental File Table) according to the ILAC G13 guidelines, and measured
by all participant laboratories for a total of 6706 determinations; some
of these samples were repeatedly assayed by all laboratories to test
also the within-laboratory variability. The list of BNP and NT-proBNP
assay methods, more frequently used by participant laboratories, were
reported in Table 1.
For the preparation of study samples, several plasma or serum
specimens were pooled together to obtain a sample pool with ﬁnal
volume of about 100 mL,whichwas immediately stored at−20 °C. Dif-
ferent materials were used, such as plasma-EDTA, plasma Li-heparin, or
serum (Supplemental File Table). Authors chose to prepare both plasma
and serum samples in order to evaluate the relative commutability of
different matrices and the possibly different degradation of peptides
in plasma or serum.
All samples were tested for the absence of HBsAg, antiHCV, and
antiHIV. Sample pools were prepared using residuals from samples
collected from apparently healthy subjects (also divided according to
gender) and patients with cardiac diseaseswith orwithout symptomatic
heart failure. Blood samples collected from approximately 30–50
subjects/patients were included in every study sample. Subjects and
patients gave the informed consensus for the use of their residual
blood samples in the study.
Study samples were sent bymail as lyophilized materials. Lyophiliza-
tion procedure was performed by Polymed (Sambuca, Firenze, Italy)
within two weeks after preparation of sample pools. Stored sample
pools, were defrosted, then distributed in approximately 150 vials (each
containing a plasma/serum volume of 0.5 mL), and ﬁnally lyophilized, as
previously reported [13]. The lyophilized materials were reconstituted
with 0.5 mL of distilled water by participant laboratories before the
assay. BNP and NT-proBNP concentrations of all the study samples were
measured before and after the lyophilization by the reference laboratory
(i.e., Laboratory of the Fondazione Regione Toscana G. Monasterio, Pisa)
in order to evaluate the recovery of lyophilization procedure and the sta-
bility of BNP and NT-proBNP in the matrix samples. The recovery
(mean±SEM) after lyophilization procedure was signiﬁcantly higher
(p=0.0006 by paired t test) for NT-proBNP assay (87.8±4.4%) than for
BNP assay (66.8±4.3%). Furthermore, the recovery was not signiﬁcantly
different between EDTA plasma (mean±SD recovery=68.1±24.7%),
heparin plasma (52.2±13.9%) or serum (64.5%) samples for BNP assay
[13]. Samples with unreliable results were discarded. In particular, only
the samples with BNP and NT-proBNP values, which showed peptide
values similar to the pathophysiological characteristics of original sam-
ples (i.e., healthy subjects, patients with moderate or more severe heart
failure) [1–3], were distributed as study samples in the survey.
2.3. Statistical analysis
Statistical analyses of the collected results were computed by the ref-
erence laboratory (i.e., Department of Laboratory Medicine, Fondazione
Table 1
List of methods more frequently used by participant laboratories for the BNP and
NT-proBNP assay.
BNP assays
1. BNP assay for ARCHITECT platform Abbott Diagnostics, Abbott Park, IL, USA. In the
last cycle (year 2011), 8% of the laboratories used this method. A total of 314 results
were produced by all the laboratories which used this BNP method, throughout all
the cycles.
2. BNP TRIAGE Biosite method for Access and UniCel DxI platforms, Beckman,
Beckman Coulter, Inc., Fullerton, CA 92835, USA. In the last cycle (year 2011),
48% of the laboratories used this method. A total of 1099 results were produced
by all the laboratories which used this BNP method, throughout all the cycles.
3. Triage Biosite BNP, Alere Inc., 51 Sawyer Road, Suite 200 Waltham, MA 02453‐
3448, USA. In the last cycle (year 2011), 13% of the laboratories used thismethod.
A total of 759 results were produced by all the laboratories which used this BNP
method, throughout all the cycles.
4. Advia Centaur BNP, Siemens Healthcare Diagnostics, TarryTown, NY 10591‐5097,
USA. In the last cycle (year 2011), 32% of the laboratories used this method. A
total of 1016 results were produced by all the laboratories which used this BNP
method, throughout all the cycles.
NT-proBNP assays
1. ECLIA NT-proBNP assay for Elecsys platform, Roche Diagnostics GmbH, D-68298
Mannheim. In the last cycle (year 2011), 32% of the laboratories used this method.
A total of 1414 results were produced by all the laboratories which used this
NT-proBNP method, throughout all the cycles.
2. ECLIA NT-proBNP assay for Modular platform, Roche Diagnostics GmbH,
D-68298 Mannheim. In the last cycle (year 2011), 41% of the laboratories
used this method. A total of 1199 results were produced by all the laboratories
which used this NT-proBNP method, throughout all the cycles.
3. NT-proBNP assay for Dimension platform, Siemens Medical Solutions Diagnostics,
TarryTown,NY10591‐5097, USA. In the last cycle (year 2011), 6% of the laboratories
used thismethod. A total of 390 results were produced by all the laboratories which
used this NT-proBNP method, throughout all the cycles.
4. NT-proBNP assay for Stratus system, Siemens Medical Solutions Diagnostics
TarryTown, NY10591‐5097USA. In the last cycle (year 2011), 5% of the laboratories
used thismethod. A total of 126 resultswere produced by all the laboratorieswhich
used this NT-proBNP method, throughout all the cycles.
5. NT-proBNP assay for VIDAS system, bioMérieux Italia Spa, Bagno a Ripoli, Italy.
In the last cycle (year 2011), 3% of the laboratories used this method. A total of
22 results were produced by all the laboratories which used this NT-proBNP
method, throughout all the cycles.
113A. Clerico et al. / Clinica Chimica Acta 414 (2012) 112–119
Author's personal copy
Regione Toscana G. Monasterio, Pisa), and then periodic and cumulative
reports were prepared and sent by mail to each participant laborato-
ry. It was also possible for the participant laboratories to ﬁnd their
individual results and the periodic and cumulative reports in a spe-
ciﬁc web site using a personal password (http://eqas.ifc.cnr.it). The
periodic reports include a scoring system, reporting the performance
of each single laboratory in comparison with those of other laborato-
ries. Moreover, each report contains some quality parameters com-
puted as follows:
1. Laboratory bias: mean percent deviations from the consensus mean
of the results the laboratory obtained for all the study samples
assayed in test period.
2. Laboratory imprecision: mean imprecision estimated from results
reported by the laboratory for unidentiﬁed replicate samples. The
mean imprecision is obtained by pooling the CVs for different replicate
pools.
3. CVT% (average between-laboratory agreement): pooled between-
laboratory CV for all the study samples mailed out in the considered
period.
4. BIAS% (average bias): the root mean square of all the laboratory
biases.
5. CVL% (average imprecision): median of all the laboratory impreci-
sions, accounting for the dispersion of the results of the laboratories
with respect to their own means.
6. Method bias: mean of the percent deviations from the consensus
mean of all the results reported by the users of the method.
7. Method imprecision: pooled CV computed from all results reported
by the users of the method.
In particular, total variability (CVT%) was estimated by averaging
the CVs computed from the results of each study sample. This vari-
ability includes both systematic between-method differences and
differences introduced by the laboratories. The imprecision of the
methods was estimated by averaging the CVs of the results produced
by the participants (using the same method) for the same study
sample. Therefore, the reported average CVs, used for the calculation of
imprecision proﬁles, were an estimate of the within-method, between-
laboratory imprecision achieved by the method during the multicentre
collaborative study. Outlier values were estimated according to the
procedure recommended by Healy [15].
3. Results
3.1. Assay methods
The most important observation regarding the CardioOrmoCheck
study is the inversion in the utilization trend of B-type natriuretic
peptide immunoassays observed in the last years of the study. Indeed,
while in the previous report [13] BNP assay methods were more uti-
lized than NT-proBNP ones (53% vs 43%), at present time, NT-proBNP
immunoassays resulted more utilized by Italian laboratories with 3446
results (51%) compared to 3260 (49%) results of BNP immunoassays. In
particular, the ECLIA system for NT-proBNP, using the Elecsys and
Modular platforms, was the most utilized method with a mean utiliza-
tion ratio of 39% (on average 76% of utilization ratio considering only
the NT-proBNP methods).
The MEIA method for the AxSYM system (Abbott Diagnostics) was
gradually replaced in the last 3 years of the study cycles by the chemi-
luminescent assay using the ARCHITECT platform (Abbott Diagnostics).
Some methods, including Immulite 2500, Vista and Stratus systems for
NT-proBNP assay, were scarcely utilized by the participant laboratories,
and so only a low number of results were available (Table 1). For this
reason, the results of thesemethodswere not considered in some statis-
tical analyses of the present study.
3.2. Variability estimation
The mean total variability (i.e., including variability among all
methods and laboratories) for BNP methods (43.0 CV%) was greatly
higher than that for NT-proBNPmethods (8.7 CV%). For BNP immunoas-
says, the mean variability, due to the difference between-methods (39.9
CV%), included the predominant part of total variability (corresponding
to 86% of total variability), being the within-method variability on
average 16.0 CV%. On the contrary, for NT-proBNP immunoassays the
within-method and between-method variabilities were 6.5 CV% and
5.8 CV%, respectively; thus suggesting that the between-method
variability contributes to the total variability less than within-method
variability (44% vs 56%, respectively).
In order to better characterize the differences in imprecision between
BNP and NT-proBNP immunoassays, we evaluated the imprecision
proﬁles of the immunoassays methods, which were more popular in
the CardioOrmoCheck study and presented an adequate number of
data for the statistical analysis (more than 350 results) (Table 2). In
particular, CV data of the MEIA method using AxSYM system and those
of the chemiluminescent assay ARCHITECT platform for BNP assay, as
well as the STRATUS, VISTA and VIDAS systems for NT-proBNP were
not analyzed owing to an inadequate number of available data. For the
other immunoassays (Table 1), the relationships (bivariate plots) be-
tween the imprecisions, expressed as CV % (Y-axis), and measured con-
centrations of the peptide (X-axis)were reported in Figs. 1 and 2 for BNP
and NT-proBNP immunoassays, respectively.
As far as the BNP methods are concerned, a great variability in the
imprecision was found between BNP immunoassays (pb0.0001 by re-
peated measures ANOVA). In particular, the TRIAGE POCT method for
BNP showed signiﬁcantly higher imprecision than the ADVIA Siemens
and TRIAGE Beckman-Coulter automated systems (pb0.0001 by
Scheffè post hoc test after ANOVA). Furthermore, we divided the 72
study samples in 3 groups according to the BNP concentrations: group
A, BNP≤50 ng/L; group B, BNP ranging from 51 to 100 ng/L; group C,
BNP>100 ng/L. The variation of CV values (dependent variable) was
signiﬁcantly explained (pb0.0001 by two way ANOVA) by differences
in both BNP values, as measured by different immunoassays, and
group concentrations. These data indicate that the imprecision of BNP
immunoassays is strongly dependent by peptide concentrations with
higher imprecision at lower values (Fig. 1). As a result, assuming a linear
relationship between CV and logarithmic transformed values of the
measured concentration, it was possible to estimate for the most com-
mon immunoassays in the survey the imprecision at the cut-off value
of 100 ng/L, which is the decisional value recommended by international
guidelines [5,7]; these data are reported in Table 2.
As far as the imprecisions of NT-proBNP immunoassays (Fig. 2) are
concerned, a lower variability of imprecision was found compared to
that of BNP immunoassays (Fig. 1). We divided the study samples in 3
Table 2
Imprecision data on the most used BNP and NT-proBNP immunoassays in the study.
System Results CV (CI 95%)a
(%)
BNP immunoassays
ADVIA Siemens 1016 10.2 (0.4–20)
POCT TRIAGE Alere 759 19.6 (2.3–36.9)
TRIAGE Beckman-Coulter 1099 9.5 (6-2–12.8)
NT-proBNP immunoassays
ECLIA Modular Roche 1199 5.7 (5.3–6.2)
ECLIA Elecsys Roche 1414 5.7 (5.2–6.2)
Dimension Siemens 390 9.9 (8.9–10.9)
a For BNP immunoassays, the CV values and the 95% respective conﬁdence intervals
(CI) were calculated at the cut-off (decisional) value (i.e. 100 ng/L) [5,7] by assuming a lin-
ear relationship between CV (dependent variable) and peptide concentration (independent
variable) values. For NT-proBNP immunoassays, the imprecision values reported in the
table represent the mean CV values and the respective conﬁdence intervals, calculated by
pooling together all control samples.
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groups according to the peptide concentrations: group A, NT-
proBNP≤800 ng/L; group B, NT-proBNP ranging from 801 to
2000 ng/l; group C, NT-proBNP values>2000 ng/L. We performed a
two way, repeated measures, ANOVA using CV values as dependent
variable and concentration groups and immunoassay methods as
two independent variables. The mean imprecision of the automated
Fig. 1. Bivariate plots of relationship between CV values (Y-axis) and BNP concentrations
(X-axis)measuredby themost popular immunoassays in the survey. Part A. Relationship be-
tween CV values and BNP concentrations measured by ADVIA Siemens automated systems.
Part B. Relationship between CV values and BNP concentrations measured by TRIAGE POCT
Aleremethod. Part C. Relationship between CV values and BNP concentrations measured by
TRIAGE Beckman-Coulter automated systems. Fig. 2. Bivariate plots of relationship between CV values and NT-proBNP concentrations
measured by the most popular immunoassays in the survey. Part A. Relationship between
CV values and NT-proBNP concentrations measured by ECLIA method by Elecsys platform
(RocheDiagnostics). Part B. Relationship betweenCVvalues andNT-proBNP concentrations
measured by ECLIAmethod by Modular platform (Roche Diagnostics). Part C. Relationship
between CV values and NT-proBNP concentrations measured by Dimension platform
(Siemens Medical Solutions Diagnostics).
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platform dimension was found to be signiﬁcantly higher (pb0.0001
by Scheffé post hoc test) than those of ECLIA methods using both
Elecsys and Modular platforms (Table 2). We found no association
(p=0.4623) between the concentration groups (independent variable)
and CV (dependent variable) by two ways, repeated measures ANOVA.
Moreover, there were no signiﬁcant correlations between CV values
and log-transformed NT-proBNP concentrations for all the immuno-
assays. As a result, assuming that the imprecision at the cut-off level
(i.e. 400 ng/L) is not signiﬁcantly different to the mean imprecision, we
estimated the 95% conﬁdence intervals of the mean imprecision for
each NT-proBNP immunoassay by pooling all data together (Table 2).
3.3. Evaluation of bias
As far as the BNP immunoassays are concerned, these methods gave
results closely related with correlation coefﬁcient values ranging from
R=0.920 (correlation between the TRIAGE POCT method and ADVIA
Siemens) to 0.981 (correlation between the TRIAGE Beckman-Coulter
system and the TRIAGE POCT method) (Table 3). However, a signiﬁcant
difference (pb0.0001 by Scheffé post hoc test after repeated measures
ANOVA using log-transformed data) was found between the mean
BNP values measured by immunoassay methods (Fig. 3A). In particular,
on average ADVIA systems (mean±SD=50.6±56.9 ng/L) showed
values about half (pb0.0001 by Scheffé test after ANOVA using log-
transformed data) than those of TRIAGE POCT method (110.6±
109.8 ng/L), TRIAGE Beckman-Coulter systems (139.6±127.2 ng/L),
andMEIAAbbott systems (93.4±100.1 ng/L), respectively. As an exam-
ple, regression line and Bland–Altman plot concerning the BNP results
obtained with ADVIA Centaur and TRIAGE Beckman-Coulter systems
are reported in Fig. 4A and B, respectively. A signiﬁcant bias, which in-
creases linearly with the increase in BNP concentration, was obtained
(Fig. 4B). Finally, the matrix effect on the results of BNP immunoassays
was also tested bymeansof twoway, repeatedmeasuresANOVA. Plasma
EDTA samples showed a signiﬁcantly different (p=0.0066) behavior
compared to the other matrices (i.e., serum and heparin samples).
These ﬁndings indicate that EDTA plasma samples are preferable for a
proﬁciency testing study, such as the CardioOrmoCheck.
As far as the NT-proBNP immunoassays are concerned, these
methods gave results closely related: the two ECLIA methods showed
a correlation R value corresponding to 0.948, while the Dimension
methods showed R values corresponding to 0.938 with ECLIA Elecsys
and to 0.982 with ECLIA Modular, respectively (Table 3). Finally, a
signiﬁcant difference (pb0.0001 by Scheffé post hoc test after repeated
measures ANOVA using log-transformed data) was also found between
themeanNT-proBNPvaluesmeasuredwith the two ECLIAmethods and
Dimension platform system, although smaller than that seen for the
BNP methods (Fig. 3B). Indeed, Dimension method showed NT-
proBNP values on average about 17% higher than the two ECLIAmethods.
Finally, the differentmatrices tested in the study (serum, EDTAor heparin
samples) did not signiﬁcantly (p=0.7688) affect the results of
NT-proBNP immunoassays, as tested by means of two way, repeated
measures ANOVA.
4. Discussion
4.1. Study protocol
Several issues should be considered when some immunoassay
methods for the measurement of B-type related natriuretic peptides
should be evaluated in a proﬁciency testing study [13]. In particular,
some critical points are the low stability in vitro of B-type biologically
active peptides, the possible matrix effects, and the evaluation of
commutability of study samples. Considering these critical issues, to
perform a reliable proﬁciency testing study for BNP and NT-proBNP
immunoassay a formidable task should be considered.
Taking into account quality speciﬁcations [16] and recommenda-
tions by manufacturers [17], several different matrices derived from
human blood samples should be used in a proﬁciency testing study
[13] for BNP and NT-proBNP immunoassays. Indeed, the quality speciﬁ-
cations for BNP assay recommend the use of EDTA plasma samples [16],
while serum should be preferred for NT-proBNP assay [16,17]. Accord-
ingly, one of the most important aims of the CardioOrmoCheck study
was the evaluation of relative commutability of different matrices.
Table 3
Correlation matrix between the values measured with the most popular BNP/NT-proBNP
methods in study samples.
Part A. BNP immunoassay methods
Methods ADVIA POCT BNP TRIAGE MEIA
ADVIA 1.000 0.920 0.941 0.975
POCT 0.920 1.000 0.981 0.930
BNP TRIAGE 0.941 0.981 1.000 0.945
MEIA 0.975 0.930 0.945 1.000
Part B. NT-proBNP immunoassay methods
Methods Elecsys Modular Dimension
Elecsys 1.000 0.948 0.938
Modular 0.948 1.000 0.982
Dimension 0.938 0.982 1.000
Fig. 3. Box (distribution) plot of BNP (Part A) and NT-proBNP (Part B) values measured
by the most popular methods of the study. The data are reported as boxes indicating
the 10th, 25th, 50th (median), 75th and 90th percentiles of BNP and NT-proBNP values
measured in the 72 study samples; the outlinerswere indicated as separated black circles.
The concentrations (Y-axis) are reported as log-scale. The levels of statistical signiﬁcance
(p values) are also indicated in the ﬁgure.
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At least to our knowledge, a primary reference material, which is
certiﬁed as commutable for all BNP and NT-proBNP immunoassays, is
not available. As a result, it is not possible to prepare secondary reference
materials, calibrators or control sampleswith a certiﬁed concentration of
the peptide [18–20]. It seems to be not reasonable to use in the present
study a procedure recommended for the preparation of primary refer-
ence materials, such as the CLSI C53-A protocol [21]. Indeed, the aim of
the present study is only to evaluate the intra- and between-assay vari-
ability of BNP and NT-proBNP immunoassays, which is an objective dif-
ferent to the more ambitious intendment to calibrate or to assess the
trueness of these methods. According to this aim, as also suggested by
other Authors [19,20], if commutable reference materials suitable for di-
rect use are lacking, the only possible alternative for establishing trace-
ability is to split human fresh samples with a laboratory performing
the reference measurement procedure. However, the reference proce-
dure for the measurement of B-type related peptides is also lacking. In
a proﬁciency study, when the reference material and method are both
lacking, the only remaining and practicable way is to compare the re-
sults of the different methods with the consensus mean, as made in
CardioOrmoCheck study. Evidently, the “consensus mean” approach
can allow only a relative estimate of bias between methods and labora-
tories. In addition, it is possible to test only the relative commutability of
study samples, distributed in the proﬁciency testing program, in com-
parisonwith the original samples collected fromhealthy subjects or pa-
tients (but not with a reference material).
It is well known that some B-type related peptides, and especially
the active peptide, BNP1–32, are greatly degradable both in vivo and
in vitro [2,3]. Preliminary data performed in the reference laboratory of
the CardioOrmoCheck study (data not shown) indicated that it is not
possible to organize a reliable proﬁciency study for BNP immunoassays,
includingmore than 100 laboratories, using frozen plasma specimens, as
study samples. As a result, in order to reduce the in vitro degradation and
to make the distribution as well as the measurement of blood samples
easier, only lyophilized plasma and serum samples were used in the
CardioOrmoCheck study. As previously reported [13], the recovery
after lyophilization procedure was signiﬁcantly higher for NT-proBNP
assay (on average 88%) than for BNP assay (on average 67%). The
lower recovery after lyophilization and the greater instability in vitro of
the BNP compared to NT-proBNP, may be, almost in part, the causes of
greater variability found between BNP and NT-proBNP immunoassays
in the present study. However, other authors [22–25] also reported a
great variability in the ratio of BNP andNT-proBNP among both individual
subjects and patients with cardiac diseases.
The term commutability has been deﬁned by the CLSI C53-A pro-
tocol “as the interassay properties of reference material, calibrator,
or trueness quality control materials that are comparable with those
demonstrated by authentic clinical specimens” [21]. In the present
study, a progressive increase in both BNP and NT-proBNP values of
the consensus means from healthy subjects to patients with severe
heart failure was found (Supplemental File Table), thus suggesting
that the study samples, used in the CardioOrmoCheck study, retained
(almost in part) the clinical information of the original blood samples.
Furthermore, the good agreement between BNP or NT-proBNPmethods,
as expressed by the correlation coefﬁcients (Table 3), found for the study
samples, was very similar to those previously reported by several
head-to-head comparisons of analytical characteristics and clinical
results of immunoassay methods performed by the reference labora-
tory of the CardioOrmoCheck study [26–34] or other laboratories
[22–25,35–37], using authentic specimens collected from healthy
subjects and patients with cardiac or extracardiac diseases.
According to the data discussed in the previous paragraphs, the re-
sults of the present study conﬁrm our preliminary data [13], suggesting
that it is possible to prepare suitable study samples for a proﬁciency
testing program by pooling human blood specimens collected from
healthy subjects or patients with cardiac disease.
4.2. Results discussion
The CardioOrmoCheck study, including results concerning 7 years
(from 2005 to 2011), indicates that the panorama of commercial BNP
and NT-proBNP methods is rapidly changing. The immunoradiometric
assay method for BNP assay by Shionogi, evaluated in the previous
study [13], is at present no more commercialized, at least in Europe.
On the other hand, the BNP method for ARCHITECT platform by Abbott,
as well as VISTA, STRATUS, and IMMULITE systems by Siemens, and
VIDAS systembyBioMérieux for proBNP assay, not evaluated in the pre-
vious study [13], have been only recently distributed and so these
“new” methods have been adopted by participating laboratories only
in the last 2 or 3 cycles of the CardioOrmoCheck study. Unfortunately,
the results concerning these “new” BNP and NT-proBNP methods are
insufﬁcient to allow a reliable statistical analysis.
Since BNP and NT-proBNP share completely different biochemical
structure,molecularweight, biological activity anddegradationpathways
Fig. 4. Part A. Linear regression between the BNP values measured with TRIAGE
Beckman-Coulter (X-axis) and ADVIA Centaur (Y-axis) systems in 68 study samples.
Part B. Linear regression (Bland–Altman plot) between the mean BNP concentration, mea-
sured with TRIAGE Beckman-Coulter and ADVIA Centaur systems (X-axis), and the differ-
ence (Y-axis) between the BNP values measured by these two methods (TRIAGE−ADVIA)
in 68 study samples.
117A. Clerico et al. / Clinica Chimica Acta 414 (2012) 112–119
Author's personal copy
[1–3,10–12], it is not surprising that BNP and NT-proBNP immunoas-
says show not only different analytical characteristics and quality
speciﬁcations, but also different clinical results. Indeed, data of the
CardioOrmoCheck study conﬁrm that there are wide differences in
both analytical performances and measured peptide values, especially
among BNP methods. These differences in the performance between
BNP and NT-proBNP immunoassays are theoretically expected because
all the commercial NT-proBNP methods tested in the study (the two
ECLIA methods and Dimension method) actually use antibodies and
standard materials from the same source (i.e., Roche Diagnostics),
while BNP methods use different antibodies and standard materials
[14,16,22].
The greater number of results obtained in the present study
allowed a more complete analysis of analytical performance of immu-
noassay methods than the previous one [13]. In particular, it was pos-
sible to evaluate the imprecision proﬁles and to calculate the
imprecision at the recommended cut-off values for the most popular
BNP and NT-proBNP immunoassays of the survey. The results of
CardioOrmoCheck study demonstrate that the imprecision around
the recommended cut-off values (corresponding to 100 ng/L for
BNP and 400 ng/L for NT-proBNP, respectively) [5,7] varies among
methods (Table 2). However, our data indicate that with the only ex-
ception of POCT method for BNP assay, all other BNP and NT-proBNP
immunoassays show an imprecision at the cut-off values lower or
around the 10% CV. On average, the NT-proBNP methods showed a
lower variability compared to BNP immunoassays. These data are well
in agreement with those previously reported in a study performed in
the reference laboratory of the CardioOrmoCheck study, which com-
pared the analytical characteristics of some BNP immunoassays with
those of the ECLIA method for NT-proBNP [27]. This difference is prob-
ably in great part due to the different biochemical characteristics of BNP
and NT-proBNP. NT-proBNP shows greater molecular mass and higher
circulating levels, and it is more stable in vivo and in vitro than BNP. As
a result, it is easier to set up a robust immunoassay method for
NT-proBNP than for BNP.
As far as the bias between the BNP immunoassays is concerned,
the results of the CardioOrmoCheck study conﬁrm that the most pop-
ular BNP immunoassays are affected by large systematic differences
(on average more than 2 fold between TRIAGE Beckman-Coulter
and ADVIA Centaur Siemens methods, Figs. 3A and 4). Wide differ-
ences between the results of BNP immunoassays were also previously
reported in a study performed in the reference laboratory of the
CardioOrmoCheck study [27]. In particular, this study found lower
BNP values measured by ADVIA Centaur and IRMA by Shionogi
methods compared to the other immunoassays, such as the POCT TRI-
AGE methods and the MEIA methods for the AxSYM platform [27].
As far as the NT-proBNP immunoassays are concerned, Di Serio et al.
[35] reported that some EDTA plasma samples (5 samples included in a
set of 65) showed unexplainable higher NT-proBNP concentrations
with Dimension platform compared to heparin plasma samples. As a re-
sult, these authors [35] suggested the use of heparin rather than EDTA
plasma samples for the measurement of NT-proBNP. Prontera et al.
[28] observed slightly but signiﬁcant lower NT-proBNP values for
EDTA plasma samples than for serum or heparin plasma samples with
the ECLIA method. As a result, the signiﬁcant bias found in the present
study between the NT-proBNP values measured by the two ECLIA
methods and the Dimension system in the study samples may be
(almost in part) due to matrix effects. However, our data indicate that
the different matrices of study samples (serum, EDTA or heparin sam-
ples) do not signiﬁcantly affect the results of NT-proBNP immunoassays.
It is important to note that Roche Diagnostics recently introduced a new
ECLIA method for the NT-proBNP assay, which uses monoclonal an-
tibodies instead of polyclonal antibodies of the previous method
[28]. A recent study performed in the reference laboratory of the
CardioOrmoCheck study [28] reported that the monoclonal ECLIA
method showed very similar analytical characteristics with slightly
lower NT-proBNP results (on average−2.5%) than the polyclonal ECLIA
method. However, the data collected so far in the CardioOrmoCheck
study are not sufﬁcient to demonstrate a signiﬁcant difference between
the results of polyclonal compared to monoclonal ECLIA method.
4.3. Prospective and conclusive remarks
The data of the CardioOrmoCheck study indicate that the panorama
of commercial BNP and NT-proBNP methods is rapidly changing. The
most important observation regarding the CardioOrmoCheck study is
the inversion in the utilization trend of B-type natriuretic peptide
immunoassays observed in the last years of the study, indicating
that in these years the NT-proBNP immunoassays resulted more utilized
by Italian laboratories than the BNP immunoassays. As suggested by
some authors [38,39], it is also conceivable that some methods, more
speciﬁc for the intact prohormone peptide (proBNP), may soon become
commercially available [40,41]. These data clearly suggest that there is not
yet available an ideal method for the measurement of B-type natriuretic
peptides. The proﬁciency testing study, such as the CardioOrmoCheck
study, may support the comparative evaluation with the aim to ﬁnd the
most reliable methods and to achieve a better harmonization between
immunoassay methods for BNP assay.
Moreover, the results of the CardioOrmoCheck study demonstrate
that there are marked differences in analytical performance and mea-
sured values especially among commercial methods for BNP assay.
Theseﬁndings suggest that itmay be not reasonable to suggest identical
cut-off or decision values for all BNP immunoassays, as recommended
by international guidelines [5,7]. Further studies are needed to conﬁrm
this observation.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.cca.2012.07.017.
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